Cover Image
市場調查報告書

Cathepsin K :開發中產品分析

Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016

出版商 Global Markets Direct 商品編碼 365732
出版日期 內容資訊 英文 49 Pages
訂單完成後即時交付
價格
Back to Top
Cathepsin K :開發中產品分析 Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016
出版日期: 2016年06月30日 內容資訊: 英文 49 Pages
簡介

本報告提供以Cathepsin K為標的之治療藥開發平台的現狀及最新更新的各開發階段比較分析,提供您最新的新聞和發表,以及企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

Cathepsin K 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:各症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • Amura Holdings Limited
  • Medivir AB
  • Merck & Co., Inc.
  • Virobay Inc.
  • Wroclawskie Centrum Badan EIT+ Sp. z o.o.

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0112TDB

Summary

Global Markets Direct's, 'Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Review, H1 2016', provides in depth analysis on Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted pipeline therapeutics.

The report provides comprehensive information on the Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38)
  • The report reviews Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) Overview
  • Therapeutics Development
    • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Stage of Development
    • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Therapy Area
    • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Indication
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Products under Development by Companies
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Companies Involved in Therapeutics Development
    • Amura Holdings Limited
    • Medivir AB
    • Merck & Co., Inc.
    • Virobay Inc.
    • Wroclawskie Centrum Badan EIT+ Sp. z o.o.
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Drug Profiles
    • AM-3701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AM-3876 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MIV-711 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • odanacatib - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit CTSK for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-129 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VBY-285 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Dormant Projects
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Discontinued Products
  • Cathepsin K (Cathepsin O or Cathepsin X or EC 3.4.22.38) - Featured News & Press Releases
    • Jan 28, 2016: Medivir initiates phase IIa study of MIV-711 in knee osteoarthritis
    • Sep 15, 2014: Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
    • Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders
    • May 21, 2013: Medivir Presents Positive Results From Phase Ia Study With MIV-711 For Treatment Of Skeletal Disorders At 2013 ECTS Annual Meeting
    • Oct 13, 2012: Merck Announces Results From Phase II Clinical Trial Of Odanacatib In Post-Menopausal Osteoporosis
    • Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders
    • Jul 11, 2012: Merck Provides Update On Phase III Trial Of Odanacatib For Treatment Of Osteoporosis
    • May 28, 2012: Medivir Initiates Phase I Clinical Trial Of MIV-711 For Treatment Of Bone Disorders
    • Mar 19, 2012: Medivir To File Application For Initiation Of Phase I Trials Of MIV-711
    • Sep 19, 2011: Merck Announces Presentation Of New Data On Odanacatib Phase III Investigational Cat-K Inhibitor For Osteoporosis At Annual Meeting Of American Society For Bone And Mineral Research
    • Oct 18, 2010: Merck Presents New Data On Odanacatib For Treatment of Osteoporosis In Postmenopausal Women at ASBMR Annual Meeting
    • Sep 16, 2009: Medivir Presented Its Cathepsin K Program at the Ongoing 31st Asbmr Meeting in Denver, USA
    • Sep 14, 2009: New, Long-Term Data For Odanacatib, Merck's Investigational Cat K Inhibitor, Showed Positive Results In Treating Osteoporosis
    • Sep 01, 2009: Medivir Broadens Its Bone Disease Portfolio By Designating One Further Candidate Drug (CD), MIV-711
    • Sep 16, 2008: Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Increased Bone Mineral Density (BMD) Over Two Years At Key Fracture Sites In Phase IIB Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Pipeline by Amura Holdings Limited, H1 2016
  • Pipeline by Medivir AB, H1 2016
  • Pipeline by Merck & Co., Inc., H1 2016
  • Pipeline by Virobay Inc., H1 2016
  • Pipeline by Wroclawskie Centrum Badan EIT+ Sp. z o.o., H1 2016
  • Dormant Projects, H1 2016
  • Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for, H1 2016
  • Number of Products under Development by Therapy Area, H1 2016
  • Number of Products under Development by Indication, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy/Combination Products, H1 2016
  • Number of Products by Stage and Mechanism of Actions, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
Back to Top